AstraZeneca’s Calquence gains FDA approval for untreated mantle cell lymphoma, supported by data showing improved survival and reduced disease progression.
FDA Approves AstraZeneca’s Calquence Combo Therapy For Untreated Mantle Cell Lymphoma
Where Today's News Shapes Tomorrow
